Skip to main content
AstraZeneca PLC logo

AstraZeneca PLC — Investor Relations & Filings

Ticker · AZN ISIN · GB0009895292 LEI · PY6ZZQWO2IZFZC3IOL08 IL Manufacturing
Open in API
Filings indexed 3,334 across all filing types
Latest filing 2020-12-17 Regulatory Filings
Country GB United Kingdom
Listing IL AZN

About AstraZeneca PLC

https://www.astrazeneca.com/

AstraZeneca PLC is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines. The company's portfolio is concentrated on several main therapy areas, including Oncology; Cardiovascular, Renal & Metabolism; and Respiratory & Immunology. AstraZeneca is committed to advancing healthcare through a robust research and development pipeline, aiming to deliver innovative medicines that address significant unmet medical needs for millions of patients worldwide. The company leverages scientific innovation to transform the future of healthcare and improve patient outcomes.

Recent filings

Filing Released Lang Actions
425 Filing
Regulatory Filings
2020-12-17 English
DIRECTOR/PDMR SHAREHOLDING
Foreign Filer Report
2020-12-16 English
Director/PDMR Shareholding
Director's Dealing Classification · 100% confidence The document is explicitly labeled with "RNS Number : 9209I" and contains a detailed disclosure regarding "Transaction by Person Discharging Managerial Responsibilities" under "Article 19 of the EU Market Abuse Regulation." This type of mandatory disclosure concerning insider trading (director/executive share transactions) is a specific regulatory filing. While it details transactions, it is not a general Director's Dealing report (DIRS) which is usually a summary form, but rather a specific regulatory notification format often disseminated via RNS. However, looking at the provided definitions, 'Director's Dealing' (DIRS) is the most specific fit for reporting personal share transactions by directors and executives. The document structure strongly aligns with regulatory reporting of insider transactions.
2020-12-16 English
IMFINZI NEW DOSE RECEIVES POSITIVE EU CHMP OPINION
Foreign Filer Report
2020-12-15 English
Imfinzi new dose receives positive EU CHMP opinion
Legal Proceedings Report Classification · 99% confidence The document is clearly identified as an RNS announcement by the header 'RNS Number : 6753I' and the closing statement referencing RNS, the news service of the London Stock Exchange. The content describes a positive opinion from the CHMP (Committee for Medicinal Products for Human Use) regarding a new dosing option for the drug Imfinzi. This is a material, time-sensitive announcement related to regulatory/clinical progress, which fits the definition of a general regulatory announcement or news release that doesn't fit a more specific category like 10-K, ER, or CT. Since it is a regulatory news service release and not a full report or a specific corporate action like a dividend or director dealing, the most appropriate classification is Regulatory Filings (RNS). The document length (11,700 chars) is substantial, but the format and source tag it as an RNS release.
2020-12-15 English
425 Filing
Regulatory Filings
2020-12-15 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.